Advertisement

Cancer Evolution as the New Frontier of Precision Medicine

  • Giuseppe Curigliano
Chapter
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 249)

Abstract

New experimental breast cancer therapies directed against novel targets are currently in clinical These experimental agents are likely to be effective for a niche of breast cancers with specific “driver mutations”. The ability to perform comprehensive molecular profiling of individual tumors has rapidly expanded over the last few years, and new DNA sequencing technologies require relatively limited quantities of fresh or archived paraffin-embedded or snap-frozen tumor tissue and provide rapid turnaround of sequencing results within a few weeks or less. All these technologies provide an unprecedented opportunity to identify patients with rare “driver” molecular alternations that are candidates for proof-of-concept clinical trials with matched targeted therapy, in the context of basket trials. The aim of this chapter on molecular profiling is to summarize the known recurrent molecular alterations in breast cancer that are potentially amenable to investigational targeted therapy, to provide an overview of the existing technological platforms for molecular profiling and ongoing or planned institutional/national screening initiatives and to outline a vision for molecular screening that may be integrated into the future activities of breast cancer research.

Keywords

Breast cancer Driver mutations Personalized medicine 

References

  1. Callaway E (2010) Cancer-gene testing ramps up. Nature 467(7317):766–767CrossRefGoogle Scholar
  2. Dias-Santagata D et al (2010) Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med 2(5):146–158CrossRefGoogle Scholar
  3. Ellis MJ et al (2007) A luminal breast cancer genome atlas: progress and barriers. J Steroid Biochem Mol Biol 106(1–5):125–129CrossRefGoogle Scholar
  4. Greenman C et al (2007) Patterns of somatic mutation in human cancer genomes. Nature 446(7132):153–158CrossRefGoogle Scholar
  5. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70CrossRefGoogle Scholar
  6. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3(8):711–715CrossRefGoogle Scholar
  7. MacConaill LE (2013) Existing and emerging technologies for tumor genomic profiling. J Clin Oncol 31(15):1815–1824CrossRefGoogle Scholar
  8. MacConaill LE et al (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4(11):e7887CrossRefGoogle Scholar
  9. Roychowdhury S et al (2011) Personalized oncology through integrative high-throughput sequencing: a pilot study. Sci Transl Med 3(111):111ra121CrossRefGoogle Scholar
  10. Sequist LV et al (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Ann Oncol 22:2616–2624CrossRefGoogle Scholar
  11. Stewart DJ, Kurzrock R (2009) Cancer: the road to Amiens. J Clin Oncol 27(3):328–333CrossRefGoogle Scholar
  12. Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458(7239):719–724CrossRefGoogle Scholar
  13. Thomas RK et al (2007) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39(3):347–351CrossRefGoogle Scholar
  14. Tran B et al (2011) Feasibility study of molecular profiling (MP) in patients (Pts) with advanced solid cancers using targeted mutation analysis and targeted exome sequencing. Mol Cancer Ther 10(Suppl 11):B48CrossRefGoogle Scholar
  15. Tsimberidou AM et al (2011) Personalized medicine in a phase I clinical trials program: the M. D. Anderson Cancer Center Initiative. J Clin Oncol 29(Suppl):Abstract CRA2500CrossRefGoogle Scholar
  16. Tuma RS (2011) Large-scale genome projects enter the clinic on both sides of the Atlantic. J Natl Cancer Inst 103(23):1730–1731CrossRefGoogle Scholar
  17. Von Hoff DD et al (2010) Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol Off J Am Soc Clin Oncol 28(33):4877–4883CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of Experimental Cancer MedicineIstituto Europeo di OncologiaMilanoItaly

Personalised recommendations